PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nppharmLink to Publisher's site
 
Neuropsychopharmacology. 2010 January; 35(1): 345–346.
Published online 2009 December 10. doi:  10.1038/npp.2009.117
PMCID: PMC2952437
NIHMSID: NIHMS241167

Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery

‘Intrinsic efficacy' (the concept that a drug acting at a single receptor is always an agonist, partial agonist, or antagonist/inverse agonist) had been accepted for a half-century. Two decades ago, it became clear that a single G protein-coupled receptor (GPCR) could have promiscuous G protein interactions. This suggested that some drugs might cause differential effects on signaling via a single receptor, and within a few years, there were data showing such ‘anomalous' functional responses—in the extreme, a ligand acting at a single receptor being a full agonist at one function and an antagonist at another (Kilts et al, 2002).

Strikingly, most laboratories engaged with this phenomenon recognized its implications, each proffering a unique name (eg, agonist-directed trafficking of signaling, biased agonism, etc), with functional selectivity emerging as the apparent consensus. The naming quandary, the involved mechanisms, the impact on understanding drug action, the relevance to drug discovery, and even the implications for teaching have been reviewed recently (Urban et al, 2007), now including the first book on the subject (Neve, 2009). It appears that this is a universal phenomenon for all GPCRs and other drug targets, and that many drugs may cause such differential signaling.

The question is whether functional selectivity is an interesting artifact for the specialist, or a mechanism that affects psychoactive drug action and drug discovery. The data suggest that both are true (Kilts et al, 2002; Smith et al, 1997). As an example, a recent publication examined the impact of functional selectivity on valvulopathy, which was thought to be due to 5-HT2B agonist-induced mitogenic action in the heart. Clinical drugs were selected for their 5-HT2B agonist profile in traditional assays, and then functionally profiled. Of this group, ropinirole was differentiated from the other compounds by its signaling profile, possibly explaining why it has a decreased risk of valvulopathy (Huang et al, 2009). To our knowledge, this is the first example for the differentiated side-effect profiles of functional selectivity.

Of direct neuropsychopharmacological relevance is the dopamine mechanism of action of aripiprazole. The most commonly disseminated hypothesis is that aripiprazole causes ‘dopamine stabilization' through D2 partial agonism. Conversely, other data have shown that aripiprazole, although sometimes a partial agonist, can also be a D2 pure antagonist or full agonist depending on the assay system. As we have reviewed recently (Mailman, 2007), the original in vivo/ex vivo data from the drug's discoverers are consistent with D2 functional selectivity, but not with simple partial agonism. Functional selectivity would thus predict that D2 ligands selected as partial agonists in a single common functional assay may not be similar clinically. From this perspective, the failure of preclamol or bifeprunox to have adequate antipsychotic efficacy may not be surprising.

The level of complexity added by functional selectivity also provides opportunity. In the short term, it permits a greater understanding of the differential neuropsychopharmacology of drugs once thought to be functionally similar, and may permit discrimination of potential drug candidates. In the long term, scientific advances showing how individual signaling pathways affect cellular function (and subsequent physiological responses) will provide a mechanistic foundation for the discovery of rationally chosen functionally selective drugs.

Footnotes

DISCLOSURE

In addition to income from his primary employer, Dr Richard Mailman has an equity interest in Biovalve Technologies and Effipharma, which creates a potential conflict of interest that has been monitored by committees at his current and previous employer. In the past three years, Dr Mailman has also been compensated for providing scientific opinions relevant to legal or public policy matters that are not related to the topic of this commentary. Except for his primary employment, Dr Vishakantha Murthy declares that no compensation or support has been received from any entity over the past three years for research or professional service. This work was supported by grants MH040537 and MH082441.

References

  • Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, et al. 2009. Parallel functional activity profiling reveals valvulopathogens are potent 5-HT2B receptor agonists: implications for drug safety assessment Mol PharmacolOnline July 1, 2009; doi:10.1124/mol.109.058057 [PubMed] [Cross Ref]
  • Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, et al. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther. 2002;301:1179–1189. [PubMed]
  • Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci. 2007;28:390–396. [PMC free article] [PubMed]
  • Neve KA. Functional Selectivity of G Protein-Coupled Receptor Ligands. Humana: New York; 2009.
  • Smith HP, Nichols DE, Mailman RB, Lawler CP. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol. 1997;323:27–36. [PubMed]
  • Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320:1–13. [PubMed]

Articles from Neuropsychopharmacology are provided here courtesy of Nature Publishing Group